^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-1248

    i
    Other names: MK-1248, MK 1248, MK1248
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    GITR agonist
    Related drugs:
    Associations

    News

    Trials
    over5years
    First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. (PubMed, Cancer)
    MK-1248 was generally well tolerated at doses up to 170 (monotherapy) and 60 mg (combination), with no DLTs or treatment-related deaths. Combination therapy provided limited antitumor responses.
    Clinical • P1 data • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Keytruda (pembrolizumab) • MK-1248